Read this story to learn about Q2- highlights, performance, earnings, dividend updates, market performance, etc.,
· The Revenues for Q2 FY’24 stood at ₹ 6,880.2 Cr · Net profit for Q2 FY’24 stood at ₹ 1,480 Cr · EBITDA is at ₹2181.3 Cr, 31.7% of Revenues
· The Revenue grew a 9% YoY · Profit after tax (PAT) saw an increment of 33% YoY · R&D Expenses stand at ₹544.7 Cr, which amounts to 7.9% of revenues
While most of the company’s sales were driven by the US market (46%), the company has witnessed lucrative sales in India (17%), emerging markets (18%), and PSAI sales (10%)
· 4 new products were launched in the US market. · 2 new ANDAs were filed with the USFDA. · European revenues grew from new products and forex.
Source: Dr. Reddy’s Laboratories Financial Report – Q2 Report, BSE